Cellebrite’s post-earnings reset creates value in a high-margin digital-forensics platform, with FedRAMP, Genesis AI, and execution recovery offering substantial upside from $11.14.
Overview
Cellebrite DI Ltd. is the leading digital-intelligence and forensic-extraction software provider, enabling public-safety and enterprise customers to collect, decode, analyze, preserve, and manage evidence from smartphones, cloud systems, computers, and drones. Its competitive advantage rests on proprietary vulnerability research, court-validated extraction methods developed over more than two decades, high switching costs, and a broad Case-to-Closure platform. **The revenue model is increasingly predictable: subscriptions and recurring term licenses represented 91% of Q2 2026 revenue, while dollar-based net retention was 117%.** Q2 revenue rose 16% year over year to $131.1 million and ARR rose 21% to $507.8 million, but ARR missed the $510 million-$513 million guide because four large cloud transactions slipped and state and local customers accepted smaller Inseyets price increases. Management cut FY2026 revenue guidance to $555 million-$561 million and ARR guidance to $550 million-$560 million, while raising Adjusted EBITDA guidance to $153 million-$159 million, or approximately 28% margin. The 31.93% post-earnings decline to $11.14 reduced forward valuation to approximately 20.2x FY2026 consensus EPS. **FedRAMP High, Genesis AI adoption, federal pipeline recovery, and execution stabilization under new CEO Shiv Ramji are the main catalysts; leadership turnover and cloud-sales timing remain the principal near-term risks.**